You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Dovato

Product menu

RUMBA logo

THE FIRST HEAD-TO-HEAD CLINICAL TRIAL vs BIC/FTC/TAF

  • 97% (79/81) and 98% (39/40) of participants in the DOVATO and BIC/FTC/TAF arms respectively had plasma HIV-1 RNA <50 copies/mL at Week 481
  • Viral reservoir (primary endpoint): Early data show no difference in the HIV-1 reservoir dynamics between DOVATO and BIC/FTC/TAF1

Switch to DOVATO from a 3-drug regimen did not increase the total or intact HIV-1 viral reservoir after 48 weeks compared with a switch from BIC/FTC/TAF1

Rumba Efficacy

Adapted from Vandekerckhove et al, 2022.1

  • checklist icon RUMBA Study Design

    MORE THAN 130 VIRLOGICALLY SUPPRESSED PATIENTS RANDOMISED TO SWITCH TO DOVATO OR STAY ON BIC/FTC/TAF

    Prospective, Single-Centre, Open-Label Randomised, Non-Inferiority Switch Study1

    Rumba Study Design

  • individual and a bottle icon Baseline Characteristics

    PEOPLE LIVING WITH HIV SWITCHED TO DOVATO OR BIC/FTC/TAF1

    The RUMBA study is a randomised trial evaluating the efficacy of DOVATO vs BIK/FTC/TAF via viral reservoirs in virologically suppressed people living with HIV

    Rumba Baseline Characteristics

    Adapted from Vandekerckhove et al, 2022. 1

References:

  1. Vandekerckhove L, Trypsteen W, Bloome E, et al. Impact of switch towards 3TC/dolutegravir on the intact and total HIV-1 viral reservoir in the Rumba study. Presented at: HIV Glasgow 2022; October 23-26, 2022; Glasgow, UK. Slides MO42.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Date of Preparation: March 2024
PM-IE-DLL-WCNT-240003